Tags
- 52 Weeks
- A
- Acute
- Acute exacerbation of chronic obstructive pulmonary disease
- Add-on
- Adult
- An
- Anemoi
- Antagonist
- Antibody
- Appropriation
- Approval
- Approved
- Approximately
- Around the World
- Asthma
- Atopic dermatitis
- Atopy
- Been Waiting
- Beta2-adrenergic agonist
- Biologic
- Blood
- Boreas
- Breath
- Cause
- Causes
- Chief
- Chief executive
- Chief executive officer
- Chronic
- Chronic obstructive pulmonary disease
- Chronic Respiratory Disease
- Clinical endpoint
- Combination
- Corticosteroid
- Cough
- Covers
- Daily activities
- Decline
- Dermatitis
- Disease
- Dupilumab
- Endpoint
- Eosinophil
- EU
- European
- European Medicines Agency
- European Union
- Evidence
- Exacerbation
- Excess
- Excessive mucus
- Executive
- Executive officer
- Follows
- ICS
- If
- Indication
- Indoor Living
- Inflammation
- Inhalation
- Inhibitor
- Interleukin 13
- Interleukin 4
- Laba
- Maintenance
- Market
- Medicine
- Moderate
- Monoclonal
- Monoclonal antibody
- Muçu
- Mucus
- Mucus production
- Muscarinic acetylcholine receptor
- Muscarinic antagonist
- Nasal
- Nasal polyp
- New
- Obstructive
- Officer
- Outline
- Pathways
- Patient
- Paul Hudson
- Perform
- Persistent
- Pharmaceutical drug
- Placebo
- Polychronion
- Polyp
- Positive
- Primary
- Production
- Progressive
- Quality
- Quality of life
- Questionnaire
- Range
- Recommendation
- Reduce
- Regeneron
- Regulation
- Regulator
- Regulatory authorities
- Regulatory submissions
- Respiratory disease
- Respiratory system
- Result
- Routine
- Saint George
- Sanofi
- Severity
- Shortness
- Shortness of breath
- Shown
- Signalling
- Sinusitis
- Spirometry
- St
- Statistical hypothesis testing
- St George
- Submission
- Sustain
- Symptom
- Symptoms
- Target
- Targeted
- Targeted therapy
- The european
- The first
- Therapy
- The world
- Thrilled
- Trial
- Trials
- Type 2
- Uncontrolled
- Underlying
- Who